What outcomes do you expect from this study? One modifiable risk factor is actually in your hands.
Amiodarone effectively treats a wide range of tachycardias but should always be prescribed with caution. Here are 3 key points to remember.
VIDEO: In a Medical News Minute, a topline review of the AHA's comprehensive guide to risk reduction in HF patients.
Drugs that improve blood pressure may have negative effects on a wide range of common comorbidities.
A new study assessed the poorly understood impact of pulmonary hypertension on mortality after myocardial infarction.
This short slide show highlights new drugs now recommended, a new HF category, and recommendations for optimizing treatment.
Researchers presented several new findings about statins and non-statins at ACC.16. This brief roundup summarizes these and other noteworthy reports.
Highlights of four recent studies in hypertension, heart failure, preeclampsia expose vulnerable populations.
PCSK9-I Patient Population and Potential  FDA-approved for relatively small patient group w/ uncontrolled LDL despite max therapy and at high risk for CVD. Familial hypercholesterolemia: ~620,000 in US.
One of the biggest advances in the world of nonvalvular atrial fibrillation was the introduction of the novel oral anticoagulants (NOACs) for decreasing thromboembolic risk.